Company Information
Industry 制造业
Company Introduction 吉林省西点药业科技发展股份有限公司设立于2001年,是一家集科研、生产、销售于一体的民营股份制制药企业。 自成立以来,公司一直秉承“诚信为本”的经营理念,恪守“防范风险、保障健康”的质量方针,发扬“热情、忠诚、执着、创新”的企业文化。全体员工艰苦奋斗,努力工作,在产品研发、生产、销售、企业运营诸多方面都取得了长足的进步,获得了良好的经济效益。 公司生产基地坐落于吉林省磐石经济开发区西点大街777号,占地136000㎡。产品领域涵盖抗贫血药物、治疗精神障碍药物、心血管疾病治疗药物及抗肿瘤治疗辅助用药等,建设有口服固体制剂生产线、冻干粉针剂生产线、原料药生产线、中药前处理及提取生产线、检测中心等,现主要生产全国品种“复方硫酸亚铁叶酸片”、新药“利培酮口腔崩解片”、“草酸艾司西酞普兰片”、“注射用唑来膦酸”等产品,其中三类新药-“复方硫酸亚铁叶酸片”获得计划项目证书。 公司严格按照GMP要求组织生产,建立了严格的质量保证体系和内部控制体系,营销网络遍布全国。
Main Business 化学药品原料药及制剂的研发、生产、销售。
Legal Representative 张俊
Top Executives
董事长:张俊
董事:孟永宏,石英秀,王致锋,刘淑敏,申太根
独立董事:吴楠楠,卢相君,苏冰
Top 5 Shareholder
Shareholder name Nature Holding Date
张俊限售股24.29%31/03/2024
鼎典投资管理(北京)有限公司-横琴鼎典股权投资基金合伙企业(有限合伙)流通A股9.45%31/03/2024
国投高科技投资有限公司流通A股5.25%31/03/2024
鼎典投资管理(北京)有限公司-横琴润汇易股权投资基金合伙企业(有限合伙)流通A股4.67%31/03/2024
珠海横琴岩合健康科技有限公司流通A股2.60%31/03/2024
Company Secretary 张银姬
Solicitors 北京海润天睿律师事务所
Auditors 大华会计师事务所(特殊普通合伙)
Tel No 0432-65888277;0431-80606619;0432-65660321
Fax No 0432-65888299;0432-65888287
Website www.xidianyy.com
Email xidianyy@ xidianyy .com
Company Address
Register: 吉林省吉林市磐石经济开发区西点大街777号
Office: 吉林省吉林市磐石经济开发区西点大街777号;吉林省长春市经开区卫星路1471号
Listing Date 23/02/2022
Shares Capital
Shares Capital: 80,803,943
Total A Share: 80,803,943
Listed A Share: 58,028,134
Non-tradable A Share: 22,775,809
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.625
DPS(RMB)* ¥ 0.260
NBV Per Share(RMB)* ¥ 12.164
Market Capitalization(RMB) 1.459B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.